CLOs on the Move

Allegro Ophthalmics

www.allegroeye.com

 
With over 100 years of combined experience, the seasoned leadership team at Allegro Ophthalmics is dedicated to delivering and establishing Integrin Peptide Therapy TM as the next generation pharmaceutical category for the treatment of wet age-related macular degeneration, diabetic retinopathy and diabetic macular edema. The potential to liberate patients from legal blindness to a much improved quality of life sustained by self-sufficient functional vision propels and accelerates our efforts.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.allegroeye.com
  • 31473 Rancho Viejo Road Suite 204
    San Juan Capistrano, CA USA 92675
  • Phone: 949.940.8130

Executives

Name Title Contact Details

Similar Companies

Transtracheal Systems Inc

Transtracheal Systems Inc is a Englewood, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Formulated Solutions

Formulated Solutions innovates, formulates, creates and comarkets consumer brands. The company has assembled a broad and talented team of experts in manufacturing, production, laboratory, regulatory, distribution and marketing, possessing an unparalleled drive to deliver market-ready products of the highest integrity. In-house technologies in Aerosol, Biochemistry, Cosmetic, Pharmaceutical and Polymer Chemistry, coupled with innovative package design and strategic marketing services, provide the company`s clients with the fastest design-to-market solution in the world.

Verinetics

Verinetics is a company that provides the DispenSecur solution for Opioid Medication Management, which offers better control for controlled substances and integrates into existing pharmacy and patient management practices.

THE PLANNING SHOP International

THE PLANNING SHOP International is a Jamison, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Galmed Pharmaceuticals

Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of Aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Aramchol is initially being developed for treating Non-Alcoholic Steato-hepatitis, or NASH, a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance. Galmed Pharmaceuticals Galmed’s business has been, in its current legal structure, was incorporated in Israel on July 31, 2013 as a privately held company. However, operating since 2000 under a different group of companies established in the same year. Galmed was co-founded by Professor Tuvia Gilat and Allen Baharaff, based on Professor Gilat’s extensive research in FABAC’s and NASH.